The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

The STOX Suite is a digital platform that standardizes the measurement of steroid-toxicity, enabling researchers and ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

Finally, the number of opportunities in the biosimilars space is very high — there are more than 300 biologics in the market, ...

PTC Therapeutics has received FDA approval for a gene therapy to treat AADC deficiency, a rare genetic disorder that impairs ...

A serious adverse event in the New York biotech’s phase 1/2 trial of its Rett syndrome gene therapy puts a question mark over ...

The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...

Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...